The China Alzheimer’s disease diagnostics market size is expected to reach USD 631.73 million by 2030, registering a CAGR of 12.1% from 2024 to 2030. The market is driven by the country’s rapidly aging population, which significantly increases the prevalence of Alzheimer’s disease. As China’s elderly population grows, the burden of age-related cognitive disorders like Alzheimer’s is intensifying, creating an urgent need for early and accurate diagnostic tools. This demographic shift has prompted a focus on expanding diagnostic capabilities and resources in urban and rural settings. Furthermore, increasing government investments and R&D studies is further propelling growth.
The government’s strategic healthcare initiatives are aimed at improving neurological health. The “Healthy China 2030” plan, ‘national dementia plan’ and other policies underscore the importance of mental health, with specific emphasis on dementia and Alzheimer’s care. As part of this framework, there is increased funding and support for research into innovative diagnostic methods, including advanced imaging technologies, biomarkers, and AI-powered cognitive assessments. Government efforts to integrate such technologies into the national healthcare system enhance accessibility to high-quality diagnostic tools, thus fostering an environment conducive to market growth.
With nearly 10 million Alzheimer's patients in China projected to rise to nearly 30 million by 2030, cognitive assessment tools are crucial for early identification and intervention, thereby enhancing Alzheimer's prevention and control efforts in the country. For instance, in September 2022, Local medical experts in Shanghai developed a digital tool to evaluate the risk of Alzheimer's disease, utilizing the MemTrax memory test and the GAMLSS statistical approach. This model establishes a normative range of metrics to assess cognitive decline across various age and educational backgrounds, facilitating large-scale screening and follow-up interventions.
Technological advancements and increasing collaboration between local and international players are further propelling the Alzheimer’s diagnostics market in China. Innovations in neuroimaging, molecular diagnostics, and digital health tools are revolutionizing the diagnostic landscape, enabling more precise detection of Alzheimer’s disease at earlier stages. In addition, partnerships between Chinese companies, research institutions, and global entities facilitate the exchange of expertise, accelerating the development and deployment of new diagnostic technologies tailored to the Chinese market. These collaborations foster a more dynamic and competitive environment, which drives innovation and enhances the overall quality and reach of Alzheimer’s diagnostics across China.
Some of the key players in the market are Quest Diagnostics, Labcorp, C2N Diagnostics, Fujirebio, Bristol Myers Squibb, Hoffmann-La Roche, Quanterix, Sysmex, Lantheus, Siemens Healthineers, and others. These players are involved in various strategic initiatives such as product launches and approval to cater to a global clientele. For instance, in May 2024, the National Medical Products Administration (NMPA) approved AriBio to conduct a Phase III clinical trial in China for its oral Alzheimer’s disease drug candidate, AR1001. This trial is likely to evaluate the safety and efficacy of AR1001, a novel drug designed to improve cognitive function in patients with mild to moderate Alzheimer's disease.
This product will be delivered within 1-3 business days.
The government’s strategic healthcare initiatives are aimed at improving neurological health. The “Healthy China 2030” plan, ‘national dementia plan’ and other policies underscore the importance of mental health, with specific emphasis on dementia and Alzheimer’s care. As part of this framework, there is increased funding and support for research into innovative diagnostic methods, including advanced imaging technologies, biomarkers, and AI-powered cognitive assessments. Government efforts to integrate such technologies into the national healthcare system enhance accessibility to high-quality diagnostic tools, thus fostering an environment conducive to market growth.
With nearly 10 million Alzheimer's patients in China projected to rise to nearly 30 million by 2030, cognitive assessment tools are crucial for early identification and intervention, thereby enhancing Alzheimer's prevention and control efforts in the country. For instance, in September 2022, Local medical experts in Shanghai developed a digital tool to evaluate the risk of Alzheimer's disease, utilizing the MemTrax memory test and the GAMLSS statistical approach. This model establishes a normative range of metrics to assess cognitive decline across various age and educational backgrounds, facilitating large-scale screening and follow-up interventions.
Technological advancements and increasing collaboration between local and international players are further propelling the Alzheimer’s diagnostics market in China. Innovations in neuroimaging, molecular diagnostics, and digital health tools are revolutionizing the diagnostic landscape, enabling more precise detection of Alzheimer’s disease at earlier stages. In addition, partnerships between Chinese companies, research institutions, and global entities facilitate the exchange of expertise, accelerating the development and deployment of new diagnostic technologies tailored to the Chinese market. These collaborations foster a more dynamic and competitive environment, which drives innovation and enhances the overall quality and reach of Alzheimer’s diagnostics across China.
Some of the key players in the market are Quest Diagnostics, Labcorp, C2N Diagnostics, Fujirebio, Bristol Myers Squibb, Hoffmann-La Roche, Quanterix, Sysmex, Lantheus, Siemens Healthineers, and others. These players are involved in various strategic initiatives such as product launches and approval to cater to a global clientele. For instance, in May 2024, the National Medical Products Administration (NMPA) approved AriBio to conduct a Phase III clinical trial in China for its oral Alzheimer’s disease drug candidate, AR1001. This trial is likely to evaluate the safety and efficacy of AR1001, a novel drug designed to improve cognitive function in patients with mild to moderate Alzheimer's disease.
China Alzheimer’s Disease Diagnostics Market Report Highlights
- Based on diagnostic techniques, the imaging techniques segment accounted for the largest revenue share of 41.40% in 2023. This high share is attributable to a significant shift towards more precise and early diagnosis, and techniques such as positron emission tomography (PET) and magnetic resonance imaging (MRI) are increasingly being utilized to identify characteristic changes in the brain, such as amyloid plaque deposition and neurofibrillary tangles, which are indicative of Alzheimer’s disease
- Based on type, diagnosis accounted for the largest revenue share of 53.49% in 2023. This growth is attributed to the rising awareness of the importance of early diagnosis in managing Alzheimer’s disease, driven by government initiatives and healthcare providers' efforts
- Based on end use, academic and research institutes dominated with the largest market share of 47.02% in 2023. The academia and institutions are at the forefront of developing new diagnostic tools and methodologies, often in collaboration with international partners. They are actively engaged in clinical trials and studies that aim to validate novel biomarkers and imaging techniques, thereby expanding the diagnostic repertoire available to clinicians
The leading players in the China Alzheimer's Disease Diagnostics market include:
- Quest Diagnostics
- Labcorb
- C2N diagnostics
- FujireBio
- Bristol Myers Squibb
- Hoffmann-La Roche
- Quanterix
- Sysmex
- Lantheus
- Siemens Healthineers
- Life Molecular Imaging
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. China Alzheimer’s Disease Diagnostics Market Variables, Trends & Scope
Chapter 4. China Alzheimer’s Disease Diagnostics Market: Diagnostics Technique Estimates & Trend Analysis
Chapter 5. China Alzheimer’s Disease Diagnostics Market: Type Estimates & Trend Analysis
Chapter 6. China Alzheimer’s Disease Diagnostics Market: End Use Estimates & Trend Analysis
Chapter 7. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players in the China Alzheimer's Disease Diagnostics market include:- Quest Diagnostics
- Labcorb
- C2N diagnostics
- FujireBio
- Bristol Myers Squibb
- Hoffmann-La Roche
- Quanterix
- Sysmex
- Lantheus
- Siemens Healthineers
- Life Molecular Imaging
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | September 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 287.76 Million |
| Forecasted Market Value ( USD | $ 631.73 Million |
| Compound Annual Growth Rate | 12.1% |
| Regions Covered | China |
| No. of Companies Mentioned | 12 |
